Christina Karas has conducted regulatory and industry research for Greenleaf since 2012. Her work informs Greenleaf’s due diligence and competitive and regulatory landscape analyses for advisory services clients, as well as the firm’s strategic guidance to pharmaceutical and biotechnology clients. Christina also writes and edits content used to develop and expand Greenleaf’s business, generate awareness of our services, and enhance our value to clients.
Christina has served as Special Assistant to the Deputy Commissioner for Policy at the Food and Drug Administration (FDA), where she supported the Agency’s policy and regulatory initiatives.
From 2006 to 2010, Christina was Manager of Health Policy at the Biotechnology Industry Organization (BIO). In this role, she contributed research, analysis, and writing to advance BIO’s policy development and advocacy across a range of issues, including the FDA review processes for biological products and molecular diagnostics, biomedical research funding, personalized medicine, and bioethics.
Additionally, she managed all governance operations and board relations for BIO’s Health Section, and helped launch and coordinate the policy activities of the board-level Working Group on Research Tools and Molecular Diagnostics.
Christina began her research career as a senior research analyst for a national political organization in Washington, D.C.
Christina has a Master’s of Public Policy from the University of Michigan’s Gerald R. Ford School of Public Policy, a Master’s in English from Boston College, and a Bachelor’s in political science from the University of Michigan (U-M), Ann Arbor. She serves on the development and communications committee for U-M’s Clements Library, a renowned archival research library, and previously taught college writing in the Boston area.